A retrospective evaluation of lomustine (CeeNU) in 32 treatment naive cats with intermediate to large cell gastrointestinal lymphoma (2006-2013)

作者：Rau S E; Burgess K E^*

来源：Veterinary and Comparative Oncology, 2017, 15(3): 1019-1028.

DOI：10.1111/vco.12243

• feline
• gastrointestinal
• lomustine
• lymphoma

Multi-drug chemotherapy protocols for feline lymphoma have demonstrated variable efficacy and tolerability. In phase I trials, lomustine has demonstrated efficacy for cats with lymphoma though its use for treatment naive feline intermediate/large cell gastrointestinal (GI) lymphoma remains unknown. This study evaluated the efficacy and tolerability of lomustine for the treatment of feline GI lymphoma. Thirty-two cats with histologically or cytologically confirmed intermediate/large cell GI lymphoma were evaluated retrospectively. Factors assessed included clinical signs, hematologic/biochemical parameters and use of L-asparaginase at induction. A response rate of 50% (16/32), with median duration of response of 302 days (range 64-1450 days), was found. Median progression-free interval was 132 days (range 31-1450 days), with overall median survival time of 108 days (range 4-1488 days). History of hyporexia, presence of anaemia and dose of lomustine were significantly associated with progression-free survival. Overall, lomustine is a well-tolerated and effective treatment for feline GI lymphoma.

• 出版日期2017-9